Compounds > 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Page last updated: 2024-11-03

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Endotoxemia

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Endotoxemia in 3 studies

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.

Endotoxemia: A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Thomas, NJ2
Carcillo, JA3
Herzer, WA2
Mi, Z2
Tofovic, SP2
Jackson, EK3
Zacharia, LC1

Other Studies

3 other studies available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Endotoxemia

ArticleYear
Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats.
    European journal of pharmacology, 2003, Mar-28, Volume: 465, Issue:1-2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Blood

2003
Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
    The Journal of pharmacology and experimental therapeutics, 1996, Volume: 279, Issue:3

    Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Blood Pressure; Cyclic AMP; Endotoxemia; He

1996
Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
    Clinical and experimental pharmacology & physiology, 2000, Volume: 27, Issue:10

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Catech

2000